IO Biotech

IO Biotech

Forskning inden for bioteknologi

Copenhagen, Denmark 5.875 følgere

Break Boundaries. Ignite Change.

Om os

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Branche
Forskning inden for bioteknologi
Virksomhedsstørrelse
51-200 medarbejdere
Hovedkvarter
Copenhagen, Denmark
Type
Aktieselskab
Grundlagt
2015
Specialer
Cancer Vaccines og Immuno-oncology

Beliggenheder

  • Primær

    Ole Maaloesvej 3

    Copenhagen, Denmark 2200, DK

    Se ruten

Medarbejdere hos IO Biotech

Opdateringer

Tilsvarende sider

Finansiering

IO Biotech 5 runder i alt

Seneste runde

Post IPO-egenkapital
Læs mere på crunchbase